Celgene bought Juno in a deal valued at about $9 billion.
Seattle biotech company Juno Therapeutics is now officially owned by Celgene, with the completion of a deal that valued Juno at about $9 billion.
Celgene, headquarted in Summit, N.J., agreed to buy Juno in January to combine resources in the cancer research field. Juno specializes in treatments that genetically modify patient’s immune cells so that they can fight off cancer.
Celgene, which already owned about 10 percent of Juno, paid $87 per share for the rest.
Juno’s leading drug candidate, called JCAR017, has shown promising results in treating Non-Hodgkin lymphoma. Celgene said it plans to expand on the research.
Most Read Business Stories
- Amazon grabs large downtown Bellevue property next to transit hub
- Largest e-recycling fraud in U.S. history sends owners of Kent firm to prison
- Boeing CEO denies any ‘technical slip’ in 737 MAX crashes, as grounding cuts into profit and cash reserves
- Peek inside the Hunts Point mansion, famous for huge art collection, that sold for record $37.5 million WATCH
- Debunking myths, shedding light on Boeing 737 MAX: Highlights from aerospace reporter Dominic Gates' Reddit AMA
Juno has about 650 employees in its South Lake Union office and a Bothell development plant; both will remain following the acquisition. Juno is hiring for about 100 open positions in the Puget Sound area, according to its website.
Juno spun out of research from the Fred Hutchinson Cancer Research Center and went public in 2014.